Changes Since Last Report — vs. v5 dated 9 Apr 2026
The prior call was directionally correct: ABCL was rated HOLD (short) / BUY (medium) / BUY (long) at $3.41 on 9 Apr; it is now $5.26, +54.3% in ~10 weeks. The rally was driven by positive interim Phase 1 data for ABCL635 (NK3R antibody for menopause vasomotor symptoms) and its advance into Phase 2. That re-rating, however, has consumed the deep-value edge — so we are downgrading the medium-term signal from BUY to HOLD, one notch, into a binary Phase 2 readout.
- Price: $3.41 → $5.26 (+54.3%) over 68 days — prior medium/long BUY validated.
- Valuation: 78 → 64 (−14) — EV/cash ~1.2× → ~1.5×, P/B 1.06 → 1.70; the stock no longer trades near net cash.
- Quality: 67 → 69 (+2) — lead asset de-risked (ABCL635 positive Ph1 → Phase 2).
- Underlying Drivers: 70 → 60, label Tailwind → Neutral — company Ph1 win offset by a risk-off sector tape and a now-binary forward.
- Timing: 55 → 53 (−2) — extended after the run; weekly/daily up, intraday pulling back.
- Signals: Medium BUY → HOLD; Short HOLD (unch.); Long BUY (unch.).
- Entry criteria: 3/5 met → 0/3 met — the sub-$3.50 value entry that was live in April is gone; now awaiting a pullback or the Ph2 catalyst.
- Analyst consensus target: $9.17 mean → $7.50 (Leerink downgraded to Market Perform; coverage thinned).
- New dominant catalyst: ABCL635 Phase 2 efficacy readout, Q3 2026 (binary); ABCL575 Phase 1 top-line Q4 2026.
DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
| Horizon | Signal | Composite Score | Confidence | Key Driver |
|---|
| Short-term (1–3 mo) |
HOLD |
59 |
55% |
Extended after a +54% run; weekly/daily uptrend but intraday rolling over and a binary Ph2 readout sits in the window |
| Medium-term (6–12 mo) |
HOLD |
62 |
55% |
One notch off BUY — good business, fair (no longer cheap) valuation; outcome hinges on the binary ABCL635 Phase 2 readout |
| Long-term (3–5 yr) |
BUY |
65 |
55% |
Quality dominates: ~$655M cash, multi-year runway, AI antibody platform + a maturing wholly-owned pipeline |
No Do-Not-Buy trigger fired. Hard-gate state: CAUTION — ongoing dilution + a binary Phase 2 clinical readout (Q3 2026). Signals come from the Quality / Valuation / Timing matrix; the driver is Neutral (no pillar adjustment).
1
Five-Pillar Scorecard
Five independent scores — each 0–100 with its own confidence. The per-horizon BUY/HOLD/SELL signals are driven by the Quality / Valuation / Timing decision matrix (with the Underlying Driver nudge — none here, as the driver is Neutral); Underlying Drivers and Economic Alignment are shown as independent lenses.
Business Quality
69
Cash-rich, AI antibody platform, de-risking pipeline — but pre-profit with lumpy legacy revenue
Confidence: 60% · Pre-adjustment: 69
Valuation Attractiveness
64
Fair, top edge — the +54% run consumed the deep-value edge; still cash-backed with Ph2 optionality
Confidence: 60% · Pre-adjustment: 64
Underlying Drivers
60
Clinical execution + biotech risk appetite — Neutral (binary forward)
Confidence: 55%
Economic Alignment
50
Neutral
Confidence: 55% · Macro report 2026-06-13
Entry/Exit Timing
53
Intermediate uptrend intact but extended; intraday pulling back into a consolidation
Confidence: 55% · Pre-adjustment: 53
Overall confidence = min(Quality 60, Valuation 60, Timing 55) = 55%. The driver is Neutral (60), so no pillar adjustment was applied.
2
Hard Gates & Do-Not-Buy Status
Binary safety checks. Any TRIGGERED gate caps the signal; CAUTION gates are notes for position sizing. The dominant risk here is a binary clinical readout, not a balance-sheet or valuation problem.
✅Financial Distress — Clear
~$655M liquidity, current ratio 14×, negligible debt. Burn ~$30M/qtr → multi-year runway.
✅Earnings Event — Clear
Q1 reported 11 May; next (Q2) ~early Aug 2026 (inferred from cadence) — >14 days out.
✅Valuation Ceiling — Clear
$5.26 is below consensus $7.50 / high $8; P/B 1.70 is not extreme; ~71% of 52w range.
⚠️Dilution / Accounting — CAUTION
Shares ~294M → 303M YoY (~3%); ESOP shelf. Typical clinical-biotech dilution; does not cap the signal.
⚠️Binary Event — CAUTION
ABCL635 Phase 2 efficacy readout (Q3 2026) is genuinely binary and could move the stock >20% either way. The defining near-term risk.
✅Severe Driver Collapse — Clear
Driver 60 (Neutral); no commodity/regulatory floor breach.
Do-Not-Buy Triggers
✅Leverage + Rising Rates — Clear
Net cash; no refinancing risk.
✅Valuation at 5-yr Extreme — Clear
Mid-range; far below multi-year highs.
✅Negative Earnings Revisions — Clear
Targets were cut, but the stock re-rated up — the "not yet repriced" condition fails.
✅Insider Selling Spike — Clear
No abnormal cluster detected.
✅Structural Business Threat — Clear
Validated VMS market (fezolinetant/elinzanetant); ABCL635 is differentiated, not obsoleted.
3
Pillar Detail: Business Quality
A deep dive into Quality: cash runway, balance sheet, the AI antibody-discovery platform moat, pipeline depth, and capital allocation. Metrics are clinical-stage-appropriate — P/E, EBITDA and revenue multiples are avoided as misleading for a pre-profit biotech.
Business Quality — Pillar Score
A well-funded, platform-backed clinical biotech whose lead asset just de-risked (ABCL635 positive Ph1 → Phase 2). The ~$655M cash pile and multi-year runway are the backbone; pre-profit status, declining legacy royalties, and a still-early pipeline cap it short of "high-conviction high."
69
Confidence 60% · base 69 → adj 69 (driver Neutral)
Lifecycle & sector: Healthcare / Biotechnology — AI-driven antibody discovery, now pivoting from a platform/royalty model to a wholly-owned clinical pipeline. Lifecycle = Clinical-Stage (lumpy legacy revenue, pre-profit, cash-funded). Macro sensitivity = Low → timing macro weight 10%.
| Sub-signal | Value | Benchmark | Score | Rationale |
|---|
| Cash runway | ~$655M liquidity · ~$30M/qtr burn | >24mo = strong | 90 | Multi-year runway (~4–5 yrs); funds the pipeline through several readouts without forced dilution. |
| Balance-sheet health | Current ratio 14× · D/E 0.15 · BVPS $3.10 | >2.0 strong | 90 | Pristine — near-zero debt, large marketable-securities buffer. Book value is ~59% of the share price. |
| Platform / moat | AI antibody-discovery engine; 200+ historic programs; Lilly relationship | — | 73 | Genuine technology moat and partnership pedigree; now applied to internal assets rather than just out-licensing. |
| Pipeline depth/quality | ABCL635 (Ph2), ABCL575 (Ph1), ABCL386/688 (IND-enabling) | — | 62 | De-risked vs April — ABCL635 first-in-class NK3R for menopause VMS, positive interim Ph1. Still early and concentrated on one lead. |
| Execution history | Pivoted to internal pipeline; hitting 2026 milestones | — | 58 | Recent execution good, but the multi-year share decline from ~$22 (2021) tempers the track record. |
| Revenue quality | ~$79M TTM, lumpy/declining (legacy royalty + licensing) | — | 35 | Not a growth driver — value rests on the pipeline and cash, not the income statement. |
Competitive Moat Scorecard — average 64
Pricing Power
55
Pre-commercial; future drug pricing depends on Ph2/3 outcomes.
Network Effects
50
N/A for a discovery platform — scored neutral.
Switching Costs
55
Partner programs embed the platform mid-discovery.
Cost Advantage
70
AI/throughput advantage in antibody discovery speed & hit rate.
Intangible Assets
78
Deep IP portfolio + proprietary discovery tech.
Capital Allocation / Management — 58
ROIC is negative (pre-profit), so the standard high-ROIC test doesn't apply. Capital allocation is disciplined for the stage — a fortress balance sheet deployed into a focused internal pipeline, with controlled dilution (~3%/yr). Founder-led (CEO Carl Hansen). The key watch-item is burn discipline as the pipeline scales.
FMP cross-reference: FMP rates ABCL C (2/5) — better than typical pre-profit biotech, lifted by a strong Price-to-Book sub-score (4) and Debt/Equity (3) that reflect the cash-backed balance sheet, while DCF/ROE/ROA/P-E sub-scores sit at 1 (unprofitable). The C rating is consistent with our "good balance sheet, unproven P&L" read.
4
Valuation Attractiveness
A deep dive into Valuation: cash-backed asset value (EV/cash, P/B), the risk-adjusted pipeline value the market is ascribing, analyst targets, grades, embedded optionality, and the FMP cross-reference. P/E, FCF yield and revenue multiples are N/A (pre-profit, lumpy revenue).
Valuation Attractiveness — Pillar Score
Fair, top edge — down hard from 78 in April. The +54% run took EV/cash from ~1.2× to ~1.5× and P/B from 1.06 to 1.70, so the "trading near net cash" thesis is spent. What remains: ~$655M cash underpins ~$1.6B market cap, and the market is paying only ~$300M for the entire clinical pipeline + AI platform — cheap if ABCL635 works, but no longer a margin-of-safety bargain.
64
Confidence 60% · base 64 → adj 64
| Lens | Reading | Score | Interpretation |
|---|
| EV / cash (primary) | ~1.5× (EV ~$955M vs ~$655M liquidity) | 62 | Up from ~1.2× in April. Still modest — you're paying ~$300M over cash for the platform + pipeline — but the deep-value floor has lifted. |
| Price / book | 1.70× (BVPS $3.10) | 60 | Reasonable for a biotech with a de-risking lead asset, but no longer near 1.0×. |
| Risk-adjusted pipeline value | ~$300M ascribed to all clinical + platform | 66 | For a Phase 2 first-in-class menopause antibody (multi-billion-dollar TAM, validated category) plus three earlier assets, the ascribed value is low — the optionality is real if Ph2 hits. |
| FCF yield | N/A (cash-burning) | N/A | Pre-profit; value rests on the asset base and pipeline, not cash generation. |
| Analyst target (10%) | Consensus $7.50 (high $8 / low $7) | 65 | $5.26 is ~43% below consensus — but targets were cut from a ~$9.17 mean (Leerink → Market Perform) and coverage is thin (2 fresh). Haircut applied. |
| Grades consensus (5%) | 9 Buy · 2 Hold · 0 Sell — 82% bullish | 68 | "Buy" consensus, but the most recent action was a downgrade (Nov 2025) and there have been no fresh actions in 30 days. |
Embedded Optionality / Free Upside
At ~$5.26 you are paying ~$1.6B for a company holding ~$655M of cash/securities; net of cash, ~$300M buys all of the following — most of it valued near zero by a market that de-rated the stock for years:
- ABCL635 (Phase 2): first-in-class NK3R antibody for menopause vasomotor symptoms — a category validated by fezolinetant (Veozah) and elinzanetant, with a multi-billion-dollar TAM. Positive interim Ph1 already in hand; Phase 2 efficacy readout Q3 2026.
- ABCL575 (Phase 1): top-line data expected Q4 2026 — a second shot on goal carried at ~$0.
- ABCL386 / ABCL688: IND-enabling — pure preclinical call options.
- The AI antibody-discovery platform + residual partnership/royalty streams (incl. the Lilly relationship), plus the ~$655M cash itself as a floor and a war-chest to in-license or buy back.
Net framing: cash + platform justify much of the EV; the clinical pipeline is the largely-unpriced upside. This is a +5 tilt (already in the 64) — it cushions the downside toward the cash floor, but with the lead asset facing a binary Ph2 it is a reason to watch, not proof the stock is cheap.
5
Underlying Drivers
The dominant external force ABCL is tethered to, scored 0–100 across history, current state, and forward outlook. The driver asymmetrically nudges the pillars only at the extremes (>80 or <20); at 60 it is Neutral and applies no adjustment.
| Horizon (weight) | Read | Score |
|---|
| Historical (25%) | Biotech (XBI) endured a multi-year drawdown but is stabilising; ABCL specifically de-rated to near-cash then rebounded sharply on the Ph1 win. | 62 |
| Current (50%) | Company-specific tailwind (positive ABCL635 Ph1, pivot-to-pipeline narrative) offset by a risk-off macro tape (stagflation regime, hawkish Fed) that is unfriendly to speculative biotech. | 62 |
| Forward (25%) | Binary. The Q3 Phase 2 efficacy readout could be a cliff or a step-change — that two-sided risk is the opposite of a momentum tailwind. | 55 |
Driver score ≈ 60 → "Neutral." No pillar adjustment (50–64 band). The qualitative call is the point: a real company tailwind is cancelled by a risk-off sector and a binary (not ramping) forward — so this is Neutral, not the Tailwind it was rated in April. Driver confidence 55% (binary forward, indirect macro linkage).
Thesis-invalidation floor: a failed ABCL635 Phase 2 efficacy readout, or runway dropping below ~2 years, breaks the case and would re-rate the stock back toward the ~$3.50 cash-plus zone.
6
Economic Alignment
How current economic conditions and capital flows help or hinder this stock, read from the latest Macro-Economic report (2026-06-13). Classified as Trend-Following (riding a tailwind) or Contrarian (fading a headwind) with a 0–100 conviction. Independent lens — it does not change the signal.
Source: GICS Healthcare sector map → XLV: Short Outperform · Medium Outperform · Long Neutral, from the MacroDriver report dated 2026-06-13. Dominant regime: Stagflation (oil shock + hawkish Fed); scenario weights Stagflation 44 / Deflationary Bust 26 / Soft Landing 18 / Reacceleration 12.
Why Neutral: the XLV "Outperform" tag reflects a defensive flight-to-safety bid on large-cap pharma/staples-like healthcare. ABCL is the opposite — a speculative, pre-profit clinical biotech that trades with XBI risk appetite, which a stagflation/risk-off regime hinders. The defensive-healthcare tailwind and the speculative-biotech headwind roughly cancel → net Neutral, conviction 50. The bet here is on a clinical outcome, not on the economy. Confidence 55% (macro report fresh, 3 days old). This lens does not move the signal.
7
Entry/Exit Timing
A deep dive into Timing: the multi-timeframe trend, risk-reward anchored to the stop, relative strength, the macro overlay at a Low sector weight (10%), sentiment, and the catalyst cluster. Read this to understand when to act.
Entry/Exit Timing — Pillar Score
Mixed-to-neutral. The intermediate trend (weekly + daily) is up and price sits well above the 200-DMA ($4.24), but the stock is extended after a +54% run, has pulled back ~23% from the $6.79 May high, and the multi-year monthly chart is still a base-in-progress. Intraday is rolling over — a consolidation, not a fresh breakout.
53
Confidence 55% · base 53 → adj 53
| Component (weight) | Reading | Score |
|---|
| MTF trend (30%) | Weekly + daily uptrend / breakout (price > SMA50 $4.65 > SMA200 $4.24); monthly still a multi-year downtrend (basing, MACD improving); intraday pulling back. | 55 |
| Risk-reward (20%) | $5.26 sits ~2.4 ATR (ATR $0.49) above the $4.20 stop zone; +24% to base $6.50, +43% to consensus $7.50. Moderate after the run. | 52 |
| Macro overlay (10%) | FOMC tomorrow (17 Jun); risk-off stagflation regime is a mild headwind for speculative biotech; VIX ~17.7. | 48 |
| Sentiment (20%) | 9 Buy / 2 Hold, but grades stale (last action a Nov-2025 downgrade). The +54% move itself reflects positive post-Ph1 sentiment. | 55 |
| Catalyst cluster (20%) | One major binary catalyst (ABCL635 Ph2, Q3) plus ABCL575 Ph1 (Q4) and FOMC (tomorrow). Focused but binary-heavy. | 50 |
Relative strength: ABCL is up ~+50% over three months — a sharp reversal from its deeply negative relative strength vs XBI in April. It has flipped to a leader, though near-term momentum is cooling off the $6.79 high.
8
Economic Event Risk
High-impact macro releases in the next ~2 weeks plus recent surprises. ABCL is a Low macro-sensitivity name, so no WAIT-for-event override is applied — but the FOMC (tomorrow) sets risk appetite for speculative biotech.
| Date | Event | Impact | Forecast / Prev | Relevant? | Why |
|---|
| 17 Jun (tomorrow) | FOMC Rate Decision + Projections | High | Hold ~3.75% / 3.75% | ⚠️ Indirect | Sets risk-on/off tone for high-beta, pre-profit biotech; a hawkish surprise pressures the cohort. |
| 16–17 Jun | Housing Starts / Retail Sales (May) | High / Med | — | No | Not relevant to a clinical biotech. |
Recent surprises (last 7 days)
| Date | Event | Actual | Forecast | Read |
|---|
| 12 Jun | Michigan Consumer Sentiment | 48.9 | 46.0 | Beat — mild risk-on. |
| 12 Jun | Michigan 1-yr Inflation Expectations | 4.6% | 4.9% | Cooler — supportive for risk assets/biotech. |
| 15 Jun | NY Empire State Manufacturing | 5.7 | 14.0 | Big miss — reinforces the stagflation regime read. |
The macro tape barely moves ABCL directly; the only near-term swing factor is whether tomorrow's FOMC turns risk appetite for speculative biotech. The dominant ABCL catalyst is clinical (Ph2), not economic.
9
Multi-Timeframe Technical Analysis
Trend, RSI, MACD and breakout status across five timeframes plus a confluence verdict. The tool flags overall "bearish" because the multi-year monthly downtrend dominates its weighting — but the actionable intermediate trend (weekly/daily) is up.
| Timeframe | Trend | RSI | MACD | Key S/R | Breakout | Vol |
|---|
| Monthly | Downtrend (basing) ↓ | 48 | −, histogram turning + | S: $3.87 · R: $6.51 / $8.05 | Resistance breakout | 0.7x |
| Weekly | Uptrend ↑ | 58 | +, rising | S: $3.86 · R: $6.51 / $6.79 | Resistance breakout | 0.1x |
| Daily | Strong uptrend ↑ | 51 | +, histogram fading | S: $4.24 (200-DMA) · R: $5.63 / $6.79 | Resistance breakout | 0.5x |
| Hourly | Downtrend ↓ | 47 | −, flat | S: $5.03 · R: $5.57 | None | 0.1x |
| 15-min | Downtrend ↓ | 47 | − | S: $5.17 · R: $5.42 | Support breakdown | 2.7x |
| Confluence: Mixed / transitioning — actionable (weekly/daily) trend up; multi-year monthly base still forming; short-term consolidating |
The picture: a multi-year downtrend that has staged a strong recovery — weekly and daily are in confirmed uptrends with price comfortably above the 200-DMA ($4.24), after a +54% run off the April lows. The pullback from the $6.79 May high into the low-$5s is a normal consolidation. Watch the $4.65–4.24 zone (SMA50 → 200-DMA) as the higher-probability re-entry support, and a daily close back above $5.63 as confirmation the uptrend has resumed.
10
Price Chart (6-Month Daily)
A 6-month daily close line with the SMA50 and key support/resistance overlaid — the visual companion to the MTF table. The February capitulation to $2.75, the steady recovery, and the May spike to $6.79 are all visible.
11
Scenario Summary
Bull / Base / Bear 12-month paths with triggers and probability weights. With a binary Phase 2 readout in the window, the distribution is unusually two-tailed.
Bull · 30% · $8.00 (+52%)
ABCL635 Phase 2 efficacy is positive — the menopause-VMS asset re-rates as a real clinical program; ABCL575 Ph1 (Q4) adds a second win. Targets revert toward the old $9+ range.
Base · 40% · $6.50 (+24%)
Phase 2 in-line/mixed; cash backing + pipeline progress support a gradual drift toward consensus. Trades around fair value $6.00 with modest upward bias.
Bear · 30% · $3.50 (−33%)
ABCL635 Phase 2 disappoints, or biotech risk-off deepens — the rally unwinds back toward the 200-DMA / net-cash floor (~$3.30–3.90).
Probability-weighted EV ≈ 0.30×8.00 + 0.40×6.50 + 0.30×3.50 = $5.85, ~+11% from $5.26 — a modest positive skew, but with a wide, binary-driven dispersion. The flat-to-positive EV with a fat left tail is exactly why the medium-term call is HOLD into the catalyst rather than BUY.
12
Entry / Exit Rules
Mechanical entry/exit conditions. Three independent entry checks (value-pullback, technical breakout, catalyst) and three exits (hard stop, thesis invalidation, profit-take). Currently 0 of 3 entry criteria met and 0 of 3 exit criteria triggered.
Entry Rule 1 — Value pullback (preferred)
BUY on a pullback into $4.24–4.65 (200-DMA → SMA50) that holds on a daily close. NOT met — price $5.26 is above the zone.
Forecast: plausible within weeks if the consolidation deepens or a hawkish Fed / soft Ph2 hint pressures the cohort.
Entry Rule 2 — Breakout continuation
BUY on a daily close above $5.63 on >1.5× average volume with RSI < 70. NOT met — $5.26, below $5.63.
Forecast: catalyst-dependent — most likely on positive Ph2 news flow.
Entry Rule 3 — Catalyst
BUY if the ABCL635 Phase 2 efficacy readout (Q3 2026) is positive. PENDING — the defining catalyst.
Forecast: Q3 2026; binary. Positive interim Ph1 raises but does not guarantee the odds.
Exit Rule 1 — Hard stop
SELL if price closes below $4.10 (under the 200-DMA $4.24 / weekly support) for 2 consecutive days. Not triggered.
Exit Rule 2 — Thesis invalidation
SELL if ABCL635 Phase 2 efficacy fails OR liquidity runway falls below ~2 years. Not triggered.
Exit Rule 3 — Profit-take / trim
Trim into $7.50–8.00 (consensus / high) if RSI > 70. Not triggered.
Imagine you act at the current price $5.26 · as of 15 Jun 2026 close
What if you bought now?
You'd be risking −$1.16 (−22%) to the $4.10 stop to gain +$1.24 (+24%) base / +$2.74 (+52%) bull.
- Risking: downside to stop $4.10 (−22%); bear case $3.50 (−33%) if Phase 2 disappoints; plus — no entry rule is met: you'd be buying ~2.4 ATR above the support zone, after a +54% run, into a binary readout.
- Gaining: base $6.50 (+24%) · bull $8.00 (+52%); plus the ~$655M cash floor (~$2.16/sh) and free pipeline optionality (ABCL635 Ph2, ABCL575 Ph1) you'd own.
- Net: risk-reward to base ≈ 1.1:1, to bull ≈ 2.4:1 — but path is binary. Read: waiting for the $4.24–4.65 zone, or for the Ph2 result, materially improves the deal versus chasing here.
What if you sold now?
You'd be locking in the +54% gain and sidestepping a binary −33% tail — at the cost of the upside if Ph2 hits.
- Giving up: base upside to $6.50 (+24%) and bull $8.00 (+52%); the cash-backed optionality; you'd sell ~12% below fair value $6.00.
- Protecting: the realised +54% and capital against the bear case ($3.50). Exit rules currently triggered? None.
- Net: no mechanical exit signal. For a holder this is a hold-into-the-catalyst zone (consider trimming a portion ahead of the binary Ph2 to manage event risk); for a new buyer, wait.
13
Position Sizing Context
Illustrative volatility context only — not advice.
Position size not computed — no allocation or portfolio role was specified. A binary Phase 2 readout argues for treating any position as speculative and sizing it so a one-day gap to the bear case is tolerable.
| Volatility context | Value | Meaning |
|---|
| Daily ATR | ~$0.49 (~9% of price) | Very volatile — a normal day moves ~9%; the Ph2 readout could gap multiples of that. |
| Beta vs SPY | 1.20 | Moderately above-market systematic risk; idiosyncratic clinical risk dominates. |
| Trailing-year range | $1.94 → $6.79 | ~250% peak-to-trough span — a high-variance name. |
14
Calibration Snapshot
Machine-readable snapshot of every score, key level, delta vs the prior report, and the watchlist Hard-Gate / Entry / Exit fields. Saved as calibration-ABCL-20260616-1230.json.
{
"ticker": "ABCL",
"exchange_ticker": "NASDAQ:ABCL",
"isin": "CA00288U1066",
"date": "2026-06-16",
"version": "v6",
"prior_report": "2026-04-09",
"user_context": { "horizon": "all", "allocation_pct": null, "portfolio_role": null },
"price_at_rating": 5.26,
"price_prior": 3.41,
"price_change_since_prior_pct": 54.3,
"signal_short": "HOLD",
"signal_medium": "HOLD",
"signal_long": "BUY",
"primary_signal": "HOLD",
"signal_medium_prior": "BUY",
"quality_score": 69,
"lifecycle_stage": "clinical-stage",
"quality_detail": {
"cash_runway": 90, "balance_sheet": 90, "platform_moat": 73,
"pipeline_depth": 62, "execution_history": 58, "revenue_quality": 35,
"moat_score": 64, "management_skin_in_game": 58
},
"valuation_score": 64,
"valuation_detail": {
"ev_to_cash": 1.46, "p_to_b": 1.70, "fcf_yield": null,
"ascribed_pipeline_value_usd_m": 300, "historical_valuation_decile": 6
},
"timing_score": 53,
"timing_detail": {
"mtf_confluence": 55, "risk_reward_score": 52,
"relative_strength_3mo": "outperform", "catalyst_clustering_score": 50,
"dynamic_macro_weight": 0.10
},
"driver_score": 60,
"driver_label": "Neutral",
"driver_score_prior": 70,
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 50,
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-06-13",
"overall_confidence": 55,
"fair_value_est": 6.00,
"stop_loss": 4.10,
"target_price": 6.50,
"target_bull": 8.00,
"target_bear": 3.50,
"analyst_consensus_target": 7.50,
"analyst_target_high": 8.0,
"analyst_target_low": 7.0,
"analyst_target_upside_pct": 42.6,
"analyst_consensus_target_prior": 9.17,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 81.8,
"analyst_coverage_count": 11,
"fmp_rating": "C",
"fmp_overall_score": 2,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"hard_gate_state": "caution",
"gates_triggered": [],
"gates_caution": ["dilution_esop", "binary_event_phase2_ABCL635_Q3_2026"],
"do_not_buy_triggers": [],
"entry_criteria_total": 3,
"entry_criteria_met": 0,
"exit_criteria_total": 3,
"exit_criteria_met": 0,
"key_catalyst": "ABCL635 Phase 2 efficacy readout Q3 2026 (binary); ABCL575 Ph1 top-line Q4 2026",
"next_check_date": "2026-07-16"
}
15
Data Sources & Methodology
Audit trail of every data source, with OK / partial / fail indicators and the confidence haircuts applied.
Data Source Status
✓
get_company_profile / get_previous_day_bar — OK ($5.26 close confirmed, 3.7M vol)
✓
get_financial_ratios / get_income_statement — OK (6 quarters)
✓
get_multi_timeframe_analysis — OK (intraday thin; discounted)
✓
get_price_target_consensus / summary — OK ($7.50; thin/cut coverage)
✓
get_grades_consensus / get_stock_grades — OK (9B/2H; stale, last Nov 2025)
✓
get_ratings_snapshot — OK (C — cash-backed)
✓
Web (Q1'26 results, pipeline, runway) — OK (ABCL635 Ph2 Q3, ABCL575 Ph1 Q4, ~$655M liquidity)
⚠
get_polygon_news — PARTIAL (feed returned mostly stale/2024 items)
⚠
get_analyst_estimates — PARTIAL (revenue/EPS usable; out-year EBITDA noisy)
✗
get_earnings_calendar — empty; next earnings (~Aug) inferred
Impact on scores: Overall confidence held at 55% (not higher): analyst targets are stale/cut and coverage is thin (Valuation conf 60), the lead-asset value hinges on a binary Phase 2 (Quality/Driver conf 55–60), and intraday technicals are thin (Timing conf 55). The polygon news feed returned stale items, so the recent-news read leans on the verified Q1'26 release and the price action itself. No failure forced a section to be dropped.
DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.